Rushnet Subsidiary HeliosDX Launches Nationwide Marketing Campaign for Monkeypox Virus Testing Services

ALPHARETTA, GA / ACCESSWIRE / August 10, 2022 / RushNet, Inc. (OTC PINK:RSHN), (the “Company”) is pleased to announce that heliosDX is expanding across the United States to promote its services in conjunction with its human virus laboratory partner Monkeypox.

heliosDX uses its SharpSpring-powered CRM to market the company and promote its services nationally. The company is launching a nationwide marketing campaign to promote its Human Monkeypox virus testing services. This growing concern and increasing outbreaks led heliosDX and its partner to act quickly and add PCR testing for the virus. The lab test is available and the kits are ready to ship.

As reported by the CDC, the virus has reached 9,492 cases in the United States as of August 9, 2022, with the hardest hit states being NY, CA, then FL. For more information on the virus and national statistics, visit:
https://www.cdc.gov/poxvirus/monkeypox/response/2022/us-map.html
https://www.cdc.gov/poxvirus/monkeypox/symptoms.html

For our clinics and practices interested in fast and reliable PCR testing services for this virus and other diseases, please visit our website or contact us directly at 1-833-HELIOS8 (833-435-4678).

For quick access to our testing services, please visit the links below.

Customer account setup:
https://heliosdx.com/account-set-up-form/

Clinical Bulletin:
https://heliosdx.com/wp-content/uploads/2022/08/heliosDX_Clinical.pdf

Requisition form:
https://heliosdx.com/wp-content/uploads/2022/07/Infectious-Disease-PCR_7822.pdf

About HeliosDx:

heliosDX is a national clinical reference laboratory offering high complexity urine drug testing (UDT), behavioral drug testing, allergy droplet maps, oral fluids and infectious diseases ( PCR). We are contracted in 44 of the lower 48 states and are looking to expand our reach and capabilities. We intend to always stay one step ahead by continuously investing in our infrastructure with the most effective scientifically proven instruments and the latest state-of-the-art software for patient and physician satisfaction. In management’s view, following these best practices is intended to enable heliosDX to provide physicians with timely and accurate reports that meet and exceed industry standards. Our goal is to excel in patient and client care through physician-designed panels that facilitate compliance testing and reporting training.

Contact:

Ashley sweatshirt
[email protected]
www.heliosdx.com
Twitter username: @dx_helios

About Grandeza Healthcare:

Grandeza Healthcare is a healthcare billing and consulting company. Provide expert billing and coding services to laboratories, medical practices, dental practices and other medical verticals. In addition to invoicing, we provide revenue cycle management (RCM) for all clients, as well as personalized consulting services. We are a rapidly growing company adding new services and value to further demonstrate our competitive advantage.

Contact:

Danielle Bauer
[email protected]
www.grandezahc.com
Twitter handle: @GrandezaHC

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that the statements and assumptions made in this press release constitute forward-looking statements and are not guarantees of future performance. Forward-looking statements are based on management’s estimates and opinions at the time the statements are made. These statements may address matters that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements after the date of this press release.

Investor Warning/Additional Risk for Investors in Companies Claiming to Be Involved in COVID-19 Related Initiatives

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Corporate Finance Division, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and self-regulatory organizations are targeting public companies that claim to have products, treatments or other strategies regarding COVID-19.

The ultimate impact of Covid-19 pandemic on the business of the Company is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with certainty, including the duration of Covid-19 outbreak. Additionally, new information may emerge regarding the severity of the COVID-19 pandemic, and any additional preventive and protective measures that governments or the Company may order, which could result in an extended period of continued business disruption. , reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further warn investors that our main objective is to fight this pandemic for the good of the world. As such, we may find it necessary to make disclosures which are consistent with this objective, but which may be contrary to the pecuniary interests of the Company and its shareholders.

THE SOURCE: RushNet, Inc.

William L. Hart